U.S. markets open in 5 hours 47 minutes

T2 Biosystems, Inc. (TTOO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1130+0.0071 (+6.70%)
At close: 04:00PM EDT
0.1060 -0.01 (-6.19%)
After hours: 07:59PM EDT

T2 Biosystems, Inc.

101 Hartwell Avenue
Lexington, MA 02421
United States
781 761 4646

IndustryDiagnostics & Research
Full Time Employees182

Key Executives

NameTitlePayExercisedYear Born
Mr. John J. Sperzel III, B.Sc.Pres, CEO & Chairman1.03MN/A1963
Mr. Alec J. BarclaySr. VP & COO544.43kN/A1980
Mr. Michael Terrence Gibbs Esq.Sr. VP & Gen. Counsel527.21kN/A1971
Mr. John M. Sprague CPAChief Financial OfficerN/AN/A1958
Ms. Kelley J. MorganChief People OfficerN/AN/A1976
Dr. Aparna Jha Ahuja M.D.Chief Medical Officer & Chairman of Scientific Advisory BoardN/AN/A1967
Mr. Brett A. GiffinChief Commercial OfficerN/AN/A1959
Dr. Roger Smith Ph.D.Sr. VP of Science R&DN/AN/A1965
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Corporate Governance

T2 Biosystems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.